TheraCryf PLC

TCF

Company Profile

  • Business description

    TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

  • Contact

    Congleton Road
    Alderley Park
    Nether AlderleyCheshireSK10 4TG
    GBR

    T: +44 1625315090

    E: [email protected]

    https://www.evgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    9

Stocks News & Analysis

stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.
stocks

ChatGPT enters the retail space and one company surges

Investors cheer the ability to purchase directly from ChatGPT.
stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,136.6015.100.17%
CAC 407,966.9571.010.90%
DAX 4024,113.62232.900.98%
Dow JONES (US)46,375.3622.53-0.05%
FTSE 1009,446.4396.001.03%
HKSE26,855.56232.680.87%
NASDAQ22,694.5434.530.15%
Nikkei 22544,550.85381.78-0.85%
NZX 50 Index13,433.99141.631.07%
S&P 5006,692.033.570.05%
S&P/ASX 2008,845.7012.300.14%
SSE Composite Index3,882.7820.250.52%

Market Movers